Personalis, Inc. — Form 8-K Summary
Business context and reporting period
This current report concerns a transaction update, not a quarterly or annual financial-results period. It reports an event dated October 2, 2026; the filing was signed October 6, 2026. Personalis develops personalized cancer testing, including tests for minimal residual disease and recurrence, genomic profiling, and biomarker research.
Transaction update
- Personalis previously agreed to be acquired by Tempus AI, Inc. through a two-step merger. If completed, Personalis will become a wholly owned subsidiary of Tempus.
- The Hart-Scott-Rodino antitrust waiting period expired at 11:59 p.m. Eastern time on October 2, 2026. This satisfies one closing condition but does not complete the merger.
- Completion remains subject to Personalis stockholder approval and satisfaction or waiver of other merger-agreement conditions. The stockholder meeting date and time have not yet been announced.
- Tempus filed Amendment No. 1 to its preliminary Form S-4 registration statement on October 2, 2026. The S-4 includes the merger proxy statement and prospectus; the filing also notes an amended Schedule 13E-3.
Financial metrics and comparison
This 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating-financial metrics, and no comparable-period financial results. It therefore provides no basis for assessing changes in Personalis's financial performance.
Outlook, risks, and contingencies
The filing does not provide financial guidance. It cautions that the proposed merger may be delayed, fail to close, or be terminated, including if stockholders do not approve it or other conditions are not met. Other identified risks include transaction costs, possible litigation, business disruption and employee or business-partner reactions, management distraction, integration challenges, and uncertainty around anticipated synergies and financing. Forward-looking statements are subject to risks and are not guarantees of future results.
Key facts for investors to verify
- Review the amended Form S-4, proxy statement/prospectus, and Schedule 13E-3 for merger terms, consideration, disclosures, and transaction-related interests.
- Confirm when the registration statement becomes effective and when the definitive proxy materials and stockholder meeting date are announced.
- Track the stockholder vote and any remaining closing conditions; HSR waiting-period expiration alone does not mean the merger has closed.
- Consult Personalis's periodic reports for current financial results, liquidity, and risks, which are not presented in this 8-K.